Drug Profile
TAK 960
Alternative Names: TAK-960Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Millennium
- Class Antineoplastics; Small molecules
- Mechanism of Action Polo-like kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Solid tumours
Most Recent Events
- 04 Feb 2013 Discontinued - Phase-I for Solid tumours in USA (PO)
- 04 Feb 2013 Discontinued - Preclinical for Acute myeloid leukaemia in USA (unspecified route)
- 01 Jan 2013 Takeda completes a phase I trial in Solid tumours (late stage disease) in USA (NCT01179399)